Prosecution Insights
Last updated: September 17, 2026
Application No. 18/551,272

NITRIFYING BACTERIA FORMULATION

Non-Final OA §101§102§103
Filed
Sep 19, 2023
Priority
Mar 31, 2021 — JP 2021-062128 +2 more
Examiner
HAMA, JOANNE
Art Unit
1645
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Jfr Co. Ltd.
OA Round
1 (Non-Final)
26%
Grant Probability
At Risk
1-2
OA Rounds
8m
Est. Remaining
64%
With Interview

Examiner Intelligence

Grants only 26% of cases
26%
Career Allowance Rate
67 granted / 262 resolved
-34.4% vs TC avg
Strong +38% interview lift
Without
With
+38.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
45 currently pending
Career history
315
Total Applications
across all art units

Statute-Specific Performance

§101
7.4%
-32.6% vs TC avg
§103
39.4%
-0.6% vs TC avg
§102
14.8%
-25.2% vs TC avg
§112
23.8%
-16.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 262 resolved cases

Office Action

§101 §102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION The claim set filed 09/19/2023 is acknowledged. The response to election / restriction filed 12/17/2025 is acknowledged. The applicant elected Group 1, claims 1-7 and 10-20, drawn to a nitrifying bacteria formulation comprising ammonia-oxidizing bacteria and nitrate-oxidizing bacteria. Claims 8-9 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 12/17/2025. The Applicant has also elected the species of a liquid culture. Claim 6-7 and 15-20 are withdrawn due to being drawn to a nonelected species. Claims 1-5 and 10-14 will be examined on the merits herein. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. However, support for the claimed invention cannot be determined because the foreign priority documents provided are not in English. Applicant cannot rely upon the certified copy of the foreign priority application to overcome any prior art rejection because a translation of said application has not been made of record in accordance with 37 CFR 1.55. When an English language translation of a non-English language foreign application is required, the translation must be that of the certified copy (of the foreign application as filed) submitted together with a statement that the translation of the certified copy is accurate. See MPEP §§ 215 and 216. Failure to provide a certified translation may result in no benefit being accorded for the non-English application. Accordingly, the filing date of the PCT application of 03/29/2022 will be used for the purpose of applying prior art. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-5 and 10-14 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a natural product without significantly more. The claims recite ammonia oxidizing bacteria of the genus Nitrosococcus and nitrite oxidizing bacteria (Nitrococcus in various dependent claims). This judicial exception is not integrated into a practical application because these bacteria naturally oxidize ammonia and nitrite and occur in nature in the same saline environments together as evidenced by Das et al. (Comparative metagenomic analysis from Sundarbans ecosystems advances our understanding of microbial communities and their functional roles) p.11. The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because bacteria of the genus Nitrosococcus are known to show ammonia nitrifying activity, under high salt concentrations, and nitrate concentrations, instant specification par. 12. The inventors do not claim any elements or limitations that would change the structure or behavior of the bacteria in the formulation in any surprising way, nor do they demonstrate evidence of such. Das provides evidence of both bacterial genera in a mangrove soil which is a high ionic liquid containing ammonia oxidizing bacteria of the genus Nitrosococcus and nitrite oxidizing bacteria of the genus Nitrococcus p.11. The notable limitations of the instant claims are drawn to specific percentages of bacteria; however, the instant application provides no evidence that those percentages would result in a surprising result over what occurs in nature. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-5 and 10-14 are rejected under 35 U.S.C. 102(a)(1) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Xiaoxi et al. (Foreign patent CN 106045016 (A) published 2016-10-26 from IDS filed 9/19/2023). Xiaoxi teaches treatment of high ammonia wastewater by converting ammonia using denitrifying bacteria par.7 and 36-37. These strains are enumerated in a liquid culture par.16,17, and comprise Nitrosococcus (5-7%) and Nitrococcus (10-15%) par.43. This composition anticipates all the limitations of claims 1-5 and 10-14. Conclusion No claims are allowed. Inquiry Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to RUDOLPH E. SLOUP Jr. IV Ph.D. whose telephone number is (571)272-7899. The examiner can normally be reached Monday to Friday, 9am to 4pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Daniel E. Kolker can be reached at (571) 272-3181. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RUDOLPH E. SLOUP Jr. IV Ph.D./ Examiner, Art Unit 1645 /DANIEL E KOLKER/Supervisory Patent Examiner, Art Unit 1645
Read full office action

Prosecution Timeline

Sep 19, 2023
Application Filed
Apr 02, 2026
Non-Final Rejection mailed — §101, §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12692322
KRAS SPECIFIC ANTIBODIES AND USES THEREOF
5y 3m to grant Granted Jul 28, 2026
Patent 12648929
COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING FILARIAL DISEASE
5y 3m to grant Granted Jun 09, 2026
Patent 12595300
ANTI-HUMAN P40 PROTEIN DOMAIN ANTIBODY AND USE THEREOF
4y 2m to grant Granted Apr 07, 2026
Patent 12559553
IL-31 MODULATORS FOR TREATING FXR-INDUCED PRURITUS
3y 8m to grant Granted Feb 24, 2026
Patent 12553897
USE OF CIRCULATING INTERLEUKIN-18 FOR PROGNOSTICATING AND TREATING RECURRENCE IN EARLY STAGE NON-SMALL CELL LUNG CANCER
3y 8m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
26%
Grant Probability
64%
With Interview (+38.2%)
3y 8m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 262 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month